Analysis on the current status and characteristic of clinical trials for oral diseases in China
10.3760/cma.j.cn112144-20241118-00433
- VernacularTitle:中国注册类口腔疾病药物临床试验现状与特征分析
- Author:
Jia JU
1
;
Yihuan LIU
;
Hongxu YANG
;
Shuibing LIU
;
Huan ZHANG
;
Zhiqiang SHI
;
Yuanming SUN
;
Bin FENG
Author Information
1. 空军军医大学口腔医院药剂科 口颌系统重建与再生全国重点实验室 国家口腔疾病临床医学研究中心 陕西省口腔生物工程技术研究中心，西安 710032
- Publication Type:Journal Article
- Keywords:
Clinical trial;
Registries;
Registered;
Oral diseases;
Drug;
Investigational new drug application
- From:
Chinese Journal of Stomatology
2025;60(4):394-402
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To understand the current status and characteristics of clinical trials for oral diseases in China, for the purpose of providing a reference for the research and development of oral diseases in China.Methods:Retrieving the information on clinical trials related to oral diseases registered on the "Platforms for drug clinical trial registration and information" of the National Medical Products Administration from the date of the database establishment to December 31, 2024. The number of clinical trials, type of drugs, trial phases, indication, trial scope, design types were statistically analyzed.Results:As of December 31, 2024, a total of 578 drug clinical trials for oral disease were registered, accounting for 2.1% (578/27 905) of the clinical trials disclosed on the platform during the same period. Bioequivalence clinical trials accounted for the highest proportion [73.9% (427/578)], followed by Phase Ⅰ [9.0% (52/578)], Phase Ⅱ [8.0% (46/578)], and Phase Ⅲ [4.5% (26/578)]. The 578 clinical trials involved 149 types of trial drugs, mainly chemical drugs, among which 127 were developed by domestic pharmaceutical enterprises and 27 by international pharmaceutical enterprises (the five investigational drugs have undergone clinical trials by both domestic and international pharmaceutical companies). The project leader units of the 578 drug clinical trials were distributed in 27 provinces, autonomous regions, municipalities, and Hong Kong Special Administrative Region. Excluding 427 bioequivalence clinical trials, the project leader units of 151 new drug clinical trials showed a significant aggregation phenomenon, and only three specialized oral hospitals have served as project leader units for drug clinical trials.Conclusions:The number of drug clinical trials for oral disease in China has generally shown an increasing trend, but there are still problems such as small number of clinical trials, low proportion of investment in new drug development and international multicenter trials, concentrated indications of clinical trials and insufficient clinical trial experience in specialized oral medical institutions. Enhancing the enthusiasm and innovation capabilities of domestic pharmaceutical enterprises in the research and development of oral diseases drugs, exploring the advantages of traditional Chinese medicine/natural medicine resources for oral diseases, and establishing a clinical research system in specialized oral medical institutions are of great significance for the development of oral drugs.
